BioSpace News Archive

Ra Medical Systems, Inc. (NYSE: RMED) , a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, announces that management will participate in the Piper Sandler 32 nd Annual Health Care Conference being held virtually on December 1-3, 2020. Investors interested in a 1x1 meeting with Ra Medical management during the conference should contact their Pip

Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2021, which ended October 30, 2020 . The company reported second quarter worldwide rev

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at two upcoming virtual investor conferences in December: Piper Sandler 32nd Annual Virtual Healthcare Conference Evercore ISI 3 rd Annual HealthCONx Virtual Conference on Thursday, December 3, 2020 at 12:10pm ET A webcast

Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman , Nevro’s Chairman, CEO and President will participate in Citi Bank’s Head Shoulders Knees and Toes Conferenc

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced that on November 23, 2020 , the NYSE American LLC (“NYSE American”), the Company’s curre

Prelude Corporation, a leader in molecular diagnostics and precision medicine for early stage breast cancer, announced that it has signed an agreement to become a provider in the America’s Choice Provider Network.

Rallybio, a clinical-stage biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced that Martin Mackay, Chief Executive Officer, Jeff Fryer, Chief Financial Officer and Steve Uden, Chief Operating Officer, will participate in a f

Vedanta Biosciences , a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced the appointment of Troy Ignelzi as an independent member of its Board of Di

PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Vedanta Biosciences, t

Appoints former Chief Medical Officer of Spark Therapeutics, Kathy Reape, M.D., and Chief Scientific Officer of Intellia Therapeutics, Laura Sepp-Lorenzino, Ph.D., to board of directors Directors bring significant gene therapy translational and development expertise ahead of GM2 gangliosidosis clinical trial initiation in 2020 and submission of four INDs by the end of 2021